MIM
APGE

MetLife Investment Management’s Apogee Therapeutics APGE Stock Holding History

MetLife Investment Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49M Buy
26,281
+2,034
+8% +$183K 0.02% 841
2026
Q1 		$2.04M Buy
24,247
+2,936
+14% +$213K 0.01% 1048
2025
Q4 		$1.61M Buy
21,311
+2,073
+11% +$131K 0.01% 1184
2025
Q3 		$764K Hold
19,238
– – ﹤0.01% 1603
2025
Q2 		$836K Sell
19,238
-3,367
-15% -$128K ﹤0.01% 1403
2025
Q1 		$845K Sell
22,605
-355
-2% -$13.7K ﹤0.01% 1446
2024
Q4 		$1.04M Buy
22,960
+1,845
+9% +$94.1K 0.01% 1387
2024
Q3 		$1.24M Buy
21,115
+80
+0.4% +$3.83K 0.01% 1266
2024
Q2 		$828K Sell
21,035
-194
-0.9% -$9.42K ﹤0.01% 1444
2024
Q1 		$1.41M Buy
21,229
+10,591
+100% +$462K 0.01% 1115
2023
Q4 		$297K Hold
10,638
– – ﹤0.01% 2009
2023
Q3 		$227K Buy
+10,638
New +$234K ﹤0.01% 2134

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

MetLife Investment Management's APGE Position: Q2 2026 in Review

MetLife Investment Management increased its Apogee Therapeutics (APGE) stake by 8.4% in Q2 2026, buying an estimated $183K and bringing the position to 26,281 shares worth $3.49M. The position accounts for 0.02% of the portfolio, ranked #841.

MetLife Investment Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • MetLife Investment Management held 26,281 shares of Apogee Therapeutics worth $3.49M as of Q2 2026.
  • MetLife Investment Management bought 2,034 Apogee Therapeutics shares in Q2 2026, an estimated $183K.
  • Apogee Therapeutics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #841 holding.
  • MetLife Investment Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.